Neither screening nor risk-based policies are perfect. As it is unclear when and for whom PCR testing or vaccination will be available, it is worth identifying the most effective policy to protect infants from invasive GBS infections. Currently, the GBS3 trial is being conducted in the UK.5 Hopefully, there soon will be clinical data available on effectiveness and cost-effectiveness, to further help the discourse on this important topic.